Advanced Liver Fibrosis

  The FDA issued a complete response letter to Intercept indicating it cannot approve the company’s new drug application for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis.

Two doses of icosabutate were well tolerated and safe in patients with nonalcoholic steatohepatitis.

The temporal change rate of proton density fat fraction and liver stiffness measurement are promising predictors for those at high risk for rapid clinical progression and may improve patient management in those with nonalcoholic fatty liver disease.

Terns Pharmaceuticals Inc. announced positive topline results from the phase 2a Lift study of TERN-101 for the treatment of patients with nonalcoholic steatohepatitis.

Using clinical bloodwork like FIB-4 and elastography technology in combination, Researchers at the International Liver congress proposed they could better identify patients with advanced fibrosis using clinical bloodwork like FIB-4 and elastography technology in combination.